Belgium-based Janssen Pharmaceutical's Tremfya (guselkumab) was found to be superior to Cosentyx (secukinumab) for the primary endpoint evaluated at week 48 of a phase three trial in adults with moderate to severe plaque psoriasis, it was reported yesterday.
The phase 3 trial, called ECLIPSE, enrolled 1,048 patients to assess the efficacy and safety of Tremfya in comparison to Cosentyx. Tremfya is an interleukin (IL)-23-targeted biologic therapy and Cosentyx is an IL-17 inhibitor owned by Novartis.
The company revealed that 84.5% of patients, who were subjected to Tremfya, had indicated an improvement of around 90% in their baseline Psoriasis Area Severity Index (PASI) score at week 48. This was in comparison to 70% of patients on treatment with Cosentyx.
Tremfya is approved in the US and Europe or the treatment of adults with moderate to severe plaque psoriasis.
4basebio announces expansion of DNA offering for personalised mRNA medicines
Rznomics reports advances in high-efficiency circRNA production in Nucleic Acids Research
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA
Thryv Therapeutics licenses new class of SGK1 inhibitors, expanding into neurodegenerative disease
Sensorion secures French approval for Phase I/II SENS-601 hearing-loss trial
Foventa makes key CMO and CFO appointments
Akeso's ivonescimab meets overall survival endpoint in interim analysis of Phase III HARMONi-2 study
Teva reports positive Phase 2a data for TEV '408 in celiac disease
Ono Pharma partners with Aitia on neurological disease drug discovery